🏢 公司NewsroomLUNGCodex · 实盘不做把握 9/10
北京时间·源无时间·以抓取为准·⟳ 抓取 04:05:48·⚡ 决策 07-29 04:42:11 +36m23s·91.1 天前
Pulmonx将参加Canaccord Genuity年度成长会议炉边谈话
公司仅公告将参加投资者会议并提供网络直播，没有披露订单、获批、业绩、融资、并购或临床/商业化新增事实。
📄 原文LUNG↗ 原文
Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader…
不做 Pulmonx（LUNG.US）
仅为投资者会议参会和网络直播安排，无明确利多/利空、无可量化基本面增量，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 low · price-in 风险 low ↗
关键理由
- 公司仅公告将参加投资者会议并提供网络直播，没有披露订单、获批、业绩、融资、并购或临床/商业化新增事实。
主要风险
- 该类会议排期通常是投资者关系日程，不构成可回测的短线交易催化。
原文全文
展开原文 · 1,672 字
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 46
th
Annual Growth Conference in Boston on Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET.
A live and archived webcast of the fireside chat will be available on “Investors” section of the Pulmonx website at
https://investors.pulmonx.com/
.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr
®
Endobronchial Valve, Chartis
®
Pulmonary Assessment System, LungTraX
®
Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr
®
Endobronchial Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit
www.Pulmonx.com
.
Pulmonx
®
, AeriSeal
®
, Chartis
®
, LungTraX
®
, StratX
®
, and Zephyr
®
are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
th
Annual Growth Conference in Boston on Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET.
A live and archived webcast of the fireside chat will be available on “Investors” section of the Pulmonx website at
https://investors.pulmonx.com/
.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr
®
Endobronchial Valve, Chartis
®
Pulmonary Assessment System, LungTraX
®
Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr
®
Endobronchial Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit
www.Pulmonx.com
.
Pulmonx
®
, AeriSeal
®
, Chartis
®
, LungTraX
®
, StratX
®
, and Zephyr
®
are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。